Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional — and often ineffective — advice ...

A doctor has revealed five Christmas foods that naturally mimic weight loss drugs like Wegovy to prevent fat gain over the holidays. These medications work by targeting GLP-1 (glucagon-like ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Kathy Bates, Oprah, Ashley Benson and more celebs who've talked about semaglutide drugs including Ozempic and Wegovy — and where they fall on its usage Kate Hogan is Director of Digital Specials ...

The diabetes and weight-loss drugs semaglutide and tirzepatide — which are generally referred to as GLP-1s and which you probably know by the names Ozempic or Wegovy, made by Novo Nordisk ...

(HealthDay News) — Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given the increased interest ...